Cargando…
Review of tipranavir in the treatment of drug-resistant HIV
Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of patients with HIV. Low adherence and toxicity among HIV-positive patients starting HAART, however, can lead to discontinuation of therapy and limit long-term treatment success. Moreover, increasing prevalence of...
Autores principales: | Streeck, Hendrik, Rockstroh, Jürgen Kurt |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374948/ https://www.ncbi.nlm.nih.gov/pubmed/18472987 |
Ejemplares similares
-
Role of tipranavir in treatment of patients with multidrug-resistant HIV
por: Courter, Joshua D, et al.
Publicado: (2010) -
Hepatic profile analyses of tipranavir in Phase II and III clinical trials
por: Mikl, Jaromir, et al.
Publicado: (2009) -
Tipranavir in the Protease Inhibitors Arena
por: Vergani, Barbara, et al.
Publicado: (2012) -
Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014) -
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure
por: Hsieh, Szu-Min, et al.
Publicado: (2009)